Wednesday, December 6, 2017

Dr. Furman on The Diminishing Role of FCR in CLL (chronic lymphocytic leukemia)

As we're getting ready to head to ASH this week, we wanted to post in response to a query that was posted originally on the CLLSLL io group forum. Dr. Richard Furman is their medical advisor and his response really puts the comparison of a therapy that has existed for decades with a therapy that is less than a decade old. You can read my commentary and the text from Dr. Furman's post https://cllsociety.org/2017/12/one-mans-opinion-fcr-vs-ibrutinib/.

We'll be going night and day at ASH and plan to post while we are there. Stay tuned.

1 Comments:

Blogger Jhon mac said...

Great information,I am very happy to your post about on. Great information,I would like to say your post is very informative.you did a wonderful thing and should be proud of yourself for sharing.Thank you! I am very happy to your post its a great post.
clinical evidence.com

May 10, 2018 at 1:58 AM  

Post a Comment

Subscribe to Post Comments [Atom]

<< Home